SCHEMBL26640500

SCHEMBL26640500

Cc1cc(Nc2ncc3c(n2)CN(C(=O)OC(C)(C)C)CC3)ccc1CS(C)(=O)=O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.56
▸ IGF1R P08069 1/20 0.43
▸ MAPK1 P28482 10/20 0.42
▸ CDK2 P24941 3/20 0.42
▸ JAK2 O60674 2/20 0.42
▸ JAK3 P52333 2/20 0.42
▸ PTK2 Q05397 2/20 0.42
▸ PDGFRB P09619 1/20 0.42
▸ DDB1 Q16531 1/20 0.41
▸ CRBN Q96SW2 1/20 0.41
▸ CCNK O75909 1/20 0.40
▸ CCNA2 P20248 1/20 0.40
▸ CCND3 P30281 1/20 0.40
▸ CDK9 P50750 1/20 0.40
▸ CDK6 Q00534 1/20 0.40
▸ NR1H2 P55055 1/20 0.40
▸ CHEK1 O14757 1/20 0.39
▸ FLT3 P36888 1/20 0.39
▸ GPR119 Q8TDV5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26640372 0.91 MAPT (0.55) MAPTIGF1RMAPK1CDK2JAK2
SCHEMBL30648754 0.91 MAPT (0.55) MAPTIGF1RMAPK1CDK2JAK2
SCHEMBL26640751 0.88 MAPT (0.52) MAPTIGF1RMAPK1CDK2JAK2
SCHEMBL26640906 0.87 MAPT (0.62) MAPTMAPK1JAK3PDGFRBDDB1
SCHEMBL26640194 0.87 MAPT (0.56) MAPTIGF1RMAPK1CDK2JAK2
SCHEMBL26640288 0.87 MAPT (0.55) MAPTMAPK1CDK2JAK2JAK3
SCHEMBL30648780 0.87 MAPT (0.55) MAPTMAPK1CDK2JAK2JAK3
SCHEMBL26640350 0.86 MAPT (0.54) MAPTMAPK1CDK2JAK2JAK3
SCHEMBL26640800 0.86 MAPT (0.58) MAPTMAPK1CDK2JAK2JAK3
SCHEMBL26640954 0.85 NR1H2 (0.46) MAPTIGF1RJAK2JAK3PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 — — EP disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS PDXK, DTYMK, HIPK1 MAPT 3283/4885IGF1R 3949/4885MAPK1 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback